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OBJECTIVES The aim of this review is to discuss the particularities of coronary artery disease (CAD), the
effect of intensive medical management and the outcome of percutaneous and surgical
revascularization in patients with diabetes mellitus (DM).
BACKGROUND CAD represents the leading cause of death in patients with DM. Numerous clinical,
biological and angiographic risk factors have been shown to be associated with CAD in
diabetic patients.
METHODS Metabolic abnormalities in patients with DM including insulin resistance, hyperglycemia and
dyslipidemia are briefly discussed. Then the potential roles of medical management and of
percutaneous and surgical coronary revascularization are more extensively reviewed.
RESULTS More vigorous control of hyperglycemia, hyperlipidemia, hypertension and other risk factors
may be of crucial importance for risk reduction. Despite remarkable progress in recent years,
the choice of a coronary revascularization strategy remains a challenge in these patients.
Diabetic patients with CAD are predisposed to higher cardiovascular events after balloon
angioplasty. Whether stenting and new antiplatelet drugs improve the results of percutaneous
revascularization in this population needs further evaluation. The superiority of the surgical
approach is also not definitely established. Therefore, many aspects of coronary revascular-
ization are still unclear in these patients.
CONCLUSIONS The results of ongoing randomized trials comparing multiple coronary stents to bypass
surgery will likely provide some answers to our questions and additional randomized trials
evaluating intensive diabetic control with or without coronary revascularization are needed to
determine the best therapeutic approach in these patients. (J Am Coll Cardiol 2000;36:
355–65) © 2000 by the American College of Cardiology
Diabetes mellitus (DM) is associated with a markedly
increased prevalence of coronary artery disease (CAD). The
overall prevalence of CAD, as assessed by various diagnostic
methods, is as high as 55% among adult patients with DM,
compared with 2% to 4% for the general population (1).
Diabetes mellitus also represents an independent risk factor
for increased mortality and morbidity (1–4). The cardiovas-
cular mortality rate is more than doubled in men and more
than quadrupled in women who have DM, compared with
their nondiabetic counterparts (2,4), and post-MI prognosis
is also worse in these patients (5–8). Moreover, DM is a
recognized risk factor for poor outcome after either percu-
taneous (9–17) or surgical (18–22) coronary revasculariza-
tion. Yet, up to 25% of patients referred for such procedures
are diabetics (9–13,15,22–27). In spite of tremendous
recent progress in these procedures, the optimal therapeutic
strategy in diabetics remains controversial (14,17).
This review describes specific aspects of CAD in diabet-
ics, particularly its clinical, angiographic, metabolic and
biological features. It also discusses the effects of intensive
medical management as well as early and late outcome after
percutaneous transluminal coronary angioplasty (PTCA)
and coronary artery bypass grafting (CABG) in an attempt
to determine an optimal therapeutic strategy in this patient
population.
Particularities of CAD in patients with DM. Several
clinical, angiographic and biological features are associated
with CAD in diabetic patients; they constitute potential risk
factors and confer a poor prognosis (4–47, Table 1).
Endothelial dysfunction (31–37), platelet and coagulation
abnormalities (38–46) and metabolic disorders (48–72)
associated with DM play a major role in the accelerated
atherosclerotic process and in the formation of coronary
thrombosis, and they contribute substantially to the com-
plex healing process after arterial wall injury. Angiographic
features related particularly to diffuse and distal coronary
disease may lead to incomplete revascularization or increase
the risk of surgical or percutaneous intervention in these
patients (9–22). The risk of morbidity and mortality is also
increased by several unfavorable clinical characteristics that
are more common in diabetic patients (6,9,11,13,26–28).
Metabolic abnormalities associated with DM. INSULIN
RESISTANCE. This metabolic syndrome, first described by
Reaven, has been proposed as a unifying concept in an
attempt to explain the different abnormalities frequently
observed in patients with non-insulin-requiring DM
(NIRDM) (48,49). It regroups hyperinsulinemia and several
cardiovascular risk factors for CAD, including abnormal
lipid profile, impaired glucose tolerance, hypertension and
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upper-body obesity (48,49). Increased plasminogen activa-
tor inhibitor-1 (PAI-1), reduced vasodilatory response to
acetylcholine and the presence of microalbuminuria have
also been described as part of this syndrome (50). The effect
of hyperinsulinemia on the occurrence of CAD has been
studied in various large prospective studies, but as yet, no
unequivocal relationship has been established (51–54). A
meta-analysis done by Ruige et al. (53), regrouping data
from 12 prospective studies evaluating this association,
found that hyperinsulinemia was a weak risk indicator for
CAD and that the relationship was influenced by patients’
ethnic background and the type of insulin assay involved in
these studies. Many cross-sectional studies have indicated
that insulin resistance is associated with ultrasonographi-
cally or angiographically assessed atherosclerosis even in the
absence of other risk factors (55–58). However, there is still
controversy about the mechanisms by which the insulin
resistance syndrome appears to induce, or at least enhance,
atherogenesis. This syndrome may be related to common
cardiovascular risk factors or may be directly accelerated by
hyperinsulinemia (44,50,52,59). Reaven hypothesized that
insulin resistance and compensatory hyperinsulinemia
might be the primary events causing hypertension, leading
subsequently to an increased risk of CAD (59). However,
the exact role of insulin remains controversial because
epidemiological and experimental data suggest that insulin
does not accelerate atherosclerosis (58,60). Moreover, recent
data suggest that impaired microvascular function may be a
central mechanism linking insulin sensitivity to increased
blood pressure, and therefore to macrovascular disease in
insulin resistance states (61).
HYPERGLYCEMIA. Traditional risk factors account only for
25%–50% of the increase in risk of CAD in diabetics (62).
Thus, there can be little doubt that hyperglycemia and lipid
abnormalities associated with DM play an important role in
the pathogenesis of CAD in these patients. Several prospec-
tive studies have reported that poor glycemic control pre-
dicts CAD risk in diabetic patients (63–65). The important
Finnish study of Lehto et al. (63) in more than 1,000
diabetic patients showed that the simultaneous presence of
high fasting blood glucose levels and abnormal lipid profile
is associated with a threefold increase in the risk of CAD
mortality and morbidity at seven years.
Hyperglycemia appears to be involved in each step of the
atherosclerotic process. Acutely it attenuates endothelium-
dependent vasodilatation in humans in vivo (66) and leads
to adverse modifications in lipid (32,62,67,68) and coagu-
lation factors (43,62). Chronic hyperglycemia can glycosyl-
ate proteins and damage the kidneys, leading to vascular
damage and secondary hypertension (32,44,62). It may also
exert direct toxic effects on the vasculature, potentiating the
development of atherosclerosis (36,44). Finally, there is
unequivocal evidence that hyperglycemia interacts with
other CAD risk factors to exacerbate the risk of CAD
mortality (2).
DYSLIPIDEMIA. Hypertriglyceridemia associated with
atherogenic, small and dense low-density lipoprotein
(LDL) cholesterol and decreased levels of high-density
lipoprotein (HDL) cholesterol are the most common ab-
normalities in type II DM (44,67). Triglycerides’ baseline
levels change with the development of diabetes, and they are
correlated with levels of fasting hyperglycemia; control of
hyperglycemia improves but does not normalize these ab-
normalities (68). Although there is still no consensus on the
best marker of CAD in diabetics (44,67,69), strategies based
essentially on LDL-cholesterol reduction in these patients
have recently provided unequivocal arguments for the role of
these abnormalities in diabetic vasculopathy (44,67,69–72).
In summary, metabolic abnormalities associated with
DM play an important role in the formation and accelera-
Abbreviations and Acronyms
DM 5 diabetes mellitus
IRDM 5 insulin-requiring diabetes mellitus
NIRDM5 non-insulin-requiring diabetes mellitus
CAD 5 coronary artery disease
CABG 5 coronary artery bypass grafting
PTCA 5 percutaneous transluminal coronary angioplasty
MI 5 myocardial infarction
TVR 5 target vessel revascularization
IMA 5 internal mammary artery
Table 1. Potential Risk Factors Associated with
Diabetes Mellitus
Clinical
Older patients (6,9,26,28)
Female gender (6,9,11,27,28)
Obese (6,9,11,26)
High prevalence of high blood pressure (9,11,13,26,28)
More severe angina (9,13)
Congestive heart failure antecedents (9,11,13,27)
Previous MI (6,13,27,28)
Previous CABG (6,26,28)
Worse post-MI prognosis (4–8)
Biological
Endothelial dysfunction (31,32) with reduced coronary flow reserve
(33–35)
Endothelial cell multiplication and migration abnormalities (36,37)
Increased platelet activity (38–40)
Increased thromboxane A2 secretion (42)
Increased platelet activated fraction (41)
Higher fibrinogen and factor VII levels (43)
Lower antithrombin III and plasma fibrinolytic activity (43)
Role of insulin and insulin-like growth factor (32,44)
High plasminogen activator inhibitor 1 (45,46)
Angiographic
Diffuse and distal CAD (6,13)
Extensive disease with angiographically small reference vessels (6,29)
Multivessel disease (5–7,9,13,26,28)
Frequent left main disease (6,13)
Poorer coronary collateral vessel development (30)
Lower ejection fraction (10,11)
More thrombus formation (47)
CAD 5 coronary artery disease; CABG 5 coronary artery bypass graft; MI 5
myocardial infarction.
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tion of atherosclerosis. Their control can possibly exert a
notable benefit in CAD prevention in these patients.
Management of CAD in patients with DM. It has been
shown that, even without prior myocardial infarction (MI),
diabetic patients have the same level of cardiovascular risk as
nondiabetics having sustained an MI (73), suggesting per-
haps that all type II diabetic patients should undergo
secondary prevention. However, there is also substantial
evidence that most patients with DM do not receive optimal
recommended treatment (74,75), especially regarding the
use of lipid-lowering drugs and angiotensin-converting
enzyme inhibitors.
BEHAVIORAL RECOMMENDATIONS. Cigarette smoking is
an independent predictor of mortality in patients with DM
(2,3,76). It is particularly hazardous in diabetic women with
insulin-requiring DM (IRDM) because it more than dou-
bles their risk of cardiac mortality (76). Cigarette smoking
cessation is strongly recommended for all diabetic patients
(2,4,75,76). Weight loss and increased physical activity are
also strongly indicated because of their beneficial effects in
improving lipid profile, insulin resistance, glycemic control,
hypertension, obesity, and platelet and coagulation abnor-
malities (75,77).
CONTROL OF HYPERGLYCEMIA. Recent studies show that
intensive glycemic control is highly effective in preventing
and retarding microvascular and, to a lesser degree, macro-
vascular complications in both type I and type II DM
(78–81). The Diabetes Control and Complications Trial
(DCCT) provided definite evidence of major reduction in
chronic microvascular complications among a group of type
I diabetic patients with tight glycemic control (78) and
suggested a potential beneficial effect of this strategy on
macrovascular disease. Tight glycemic control reduced ma-
jor macrovascular events by one-half in diabetics compared
with conventionally treated patients (79). However, this
reduction did not reach statistical significance. The random-
ized United Kingdom Prospective Diabetes Study
(UKPDS) (80) has reported that, over 10 years of follow-up,
intensive glycemic control by either insulin or sulphonyl-
ureas significantly reduced (by 25%) the risk of microvas-
cular complications in NIRDM patients. Diabetes-related
mortality and MI incidence were also reduced by 10% and
16% respectively, but these reductions did not reach statis-
tical significance (80). A similar reduction was observed in
diet-treated obese NIRDM patients taking metformin (81).
In addition, a recent retrospective study has reported that
optimal glycemic control in diabetic patients can favorably
influence major cardiac events following PTCA (82).
LIPID-LOWERING THERAPY. Although no published studies
have specifically investigated the effects of lipid-lowering
therapy on the development of CAD in diabetic patients,
some solid arguments support the efficacy of this therapy in
primary and secondary prevention trials (69–72). A sub-
group analysis of the Scandinavian Simvastatin Survival
Study (4S) (70) indicated that, in diabetic patients with
hypercholesterolemia, normal triglycerides and established
CAD, lowering LDL-cholesterol levels with the HMG
CoA reductase inhibitor simvastatin was associated with a
marked reduction of major CAD and related atherosclerotic
events. Five-year mortality was decreased by 43% in diabetic
versus 29% in nondiabetic patients. Similar outcomes were
reported by the Cholesterol And Recurrent Events (CARE)
trial (71), evaluating the benefits of pravastatin in patients
with average cholesterol levels after MI. There was a greater
benefit of pravastatin in diabetics than in nondiabetics, with
greater relative risk reduction for CAD major events and for
revascularization procedures during a five-year follow-up.
Finally, in the Long-term Intervention with Pravastatin in
Ischemic Disease (LIPID) trial (72), pravastatin therapy
also showed a 19%, albeit not statistically significant, reduc-
tion of the composite end point of CAD-related death and
MI during a 6.1-year follow-up in a subgroup of diabetics
with a history of MI or unstable angina and with a broad
range of initial cholesterol levels.
CONTROL OF HYPERTENSION. Recent studies have shown
that adequate blood pressure control markedly reduced
major cardiovascular events related to macrovascular com-
plications (83–86). An important beneficial effect on mi-
crovascular disease was also demonstrated in the UKPDS
study, where blood pressure was controlled by beta-blockers
or angiotensin-converting enzyme inhibitors (84). How-
ever, there is still some uncertainty concerning blood pres-
sure levels needed for maximal benefit, as well as the optimal
drug classes to be used in these patients (44,83,87). The
recently revised guidelines for the treatment of hypertension
by the Joint National Committee on Prevention, Detection,
Evaluation and Treatment of High Blood Pressure recom-
mended a level around 130/85 mm Hg for diabetic patients,
which is compatible with the smallest decline in renal
function in these patients (83,87). First-line therapy should
be based on cardioselective beta-blockers and diuretics that
have been convincingly shown to reduce mortality and
morbidity in patients with diabetic nephropathy and in
NIRDM patients (83). Angiotensin-converting enzyme
inhibitors and calcium channel blocking agents can be
added as second-line therapy. (83,87).
Other therapeutic considerations. THROMBOLYTIC
AGENTS. Recent studies have confirmed that DM is a major
independent predictor of acute and long-term post-MI
mortality and morbidity, particularly in women and in
IRDM patients (5–8). Numerous factors, including more
severe CAD, associated comorbidity, metabolic derange-
ments, silent ischemia and late or atypical presentation may
contribute to a lesser use of fibrinolytic agents (88) and to a
worse post-MI prognosis in these patients (5,6). An over-
view by the Fibrinolytic Therapy Trialists’ Collaborative
Group (89), including 43 073 patients among whom 4,529
were diabetics, confirmed the benefit of thrombolysis in
diabetic patients. The absolute reduction in mortality was
357JACC Vol. 36, No. 2, 2000 Hammoud et al.
August 2000:355–65 Management of Coronary Artery Disease in Patients With Diabetes
greater in diabetics than in nondiabetics (3.7% vs. 2.1%)
despite a greater 35-day mortality rate in diabetics (13.6%
vs. 8.7%). Diabetics also had a slightly greater absolute
increase, albeit not statistically significant, in the risk of
haemorrhagic stroke (0.6% vs. 0.4%), but vitreous hemor-
rhage was rare. Data from a recent British study suggest that
retinopathy is not a contraindication to thrombolysis except
in the presence of a recent vitreous hemorrhage (90).
INSULIN-GLUCOSE INFUSION. Long-term mortality in dia-
betic patients hospitalized for acute MI may be reduced by
an insulin-glucose infusion followed by multidose insulin
treatment, as demonstrated recently by a Swedish prospec-
tive study (91,92). Insulin therapy appears to beneficially
influence all cardiovascular causes of mortality, with a
particular impact on fatal reinfarction and left ventricular
failure (91). Another recent study reported a favorable
mortality trend following glucose-insulin-potassium infu-
sion in acute MI patients given reperfusion therapy (93).
ANTIPLATELET AGENTS AND ANTICOAGULANTS. Platelet
and coagulation abnormalities contribute to CAD in dia-
betics (5,38,62). Although more clinical trials are needed,
current evidence supports antiplatelet therapy for diabetics.
The meta-analysis of the Antiplatelet Trialists’ Collabora-
tion Group included 47 000 patients (10% diabetics) and
reported an important benefit of aspirin therapy in diabetics
with or at an increased risk for vascular disease (94). The
combined end point of vascular death, MI or stroke was
22.3% in the control group and 18.5% in those receiving
aspirin. The magnitude of this benefit in diabetics was
similar to that observed in nondiabetics, without an excess
in bleeding complications.
Recent trials have shown that low-molecular-weight
heparins are more effective than placebo and as beneficial as
or more beneficial than unfractionated heparin in the acute
treatment of patients with unstable angina or non-Q-wave
MI (95–97). In general, these studies show a consistent
treatment effect among patient subgroups, and the
ESSENCE trial in particular has shown comparable bene-
fits in patients with or without DM (98). In the TIMI 11B
trial, the superiority of enoxaparin over unfractionated
heparin in preventing death and cardiac ischemic events was
greatest in high-risk patients (99). In the GUSTO IIB trial,
hirudin, a direct thrombin inhibitor, was modestly more
effective than unfractionated heparin in the treatment of
diabetic patients with acute coronary syndromes and was
not associated with an increased risk (100).
Recent clinical trial evidence suggests that glycoprotein
IIb/IIIa inhibitors reduce the early and mid-term incidence
of death, MI and recurrent angina in patients with unstable
angina or non Q-wave MI (101–105). In PRISM-PLUS,
the reduction in clinical events in the group receiving
tirofiban plus heparin compared with that receiving
heparin-only was important for both DM and non-DM
subgroups (102). However, as compared with heparin ther-
apy only, combination therapy reduced the secondary end
point of death and MI to a much greater extent (88% versus
43%, p 5 0.005) in diabetics than in the overall study
population (103). In the PURSUIT study, death and
nonfatal MI were also significantly reduced by eptifibatide
therapy as compared with placebo in both DM and
non-DM subgroups (104). However, compared with non-
diabetics, 30-day mortality was significantly more reduced
in IRDM patients (105). Finally, a meta-analysis pooling all
diabetic patients in 10 recent clinical trials of the effects of
glycoprotein IIb/IIIa antagonists showed that diabetics had
twice the absolute reduction in event rates seen in nondia-
betics (106). There was a trend favoring a DM interaction
that, however, did not reach statistical significance. The
efficacy and benefits of glycoprotein IIb/IIIa inhibitors in
diabetic patients undergoing percutaneous coronary inter-
ventions are discussed in the next section.
BETA-BLOCKERS. Pooled trial results of beta-blockers given
soon after MI have shown a 37% mortality reduction in
diabetics compared with 13% in all treated patients, and a
similar beneficial decrease in the incidence of reinfarction
(107). These drugs are also effective in reducing mortality
when given long-term after MI (107,108).
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. Sub-
group analysis of several studies have suggested that
angiotensin-converting enzyme inhibition in diabetics with
acute MI is associated with larger reductions in short-term
mortality and occurrence of congestive heart failure than in
nondiabetic patients (109,110). Similar data support an
important long-term benefit of these drugs in diabetics
suffering from acute MI with left ventricular dysfunction
(111,112). Recent results from the Danish TRACE study
showed that angiotensin-converting enzyme inhibition after
MI complicated by left ventricular dysfunction in diabetics
saved lives and substantially reduced the risk of progression
to severe heart failure (112). Furthermore, diabetic patients
represent fairly large subgroups of congestive heart failure
patients in whom angiotensin-converting enzyme inhibitors
were extensively evaluated. In these studies, angiotensin-
converting enzyme inhibitors often reduced mortality and
morbidity even more in diabetic than in nondiabetic pa-
tients (113).
The final results of the Heart Outcome Prevention
Evaluation (HOPE) study were reported recently
(114,115). In this trial, a predefined subgroup of 3,657
middle-aged diabetic patients at risk for renal and cardio-
vascular disease was randomized to receive the angiotensin-
converting enzyme inhibitor ramipril or a placebo for four
years. The primary end point of cardiovascular mortality,
MI and stroke was reduced by 24% and mortality alone was
reduced by 38% in the angiotensin-converting enzyme
inhibitor group. Diabetic complications and microvascular
disease were reduced by 17%. An important finding of this
trial is that the reduction of outcome events was similar in
patients with or without left ventricular dysfunction (115).
In summary, data from recent prospective studies have
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provided solid arguments for intensive glycemic, lipid and
blood pressure control in diabetics. In addition, several
evidence-based pharmacological treatment strategies have
been convincingly shown to confer major benefit on mor-
bidity and mortality in diabetic patients with CAD. Addi-
tional randomized studies should evaluate the role of tight
metabolic control on reduction of major cardiovascular
events with or without coronary revascularization.
Percutaneous coronary revascularization in patients with
symptomatic CAD and DM. ROLE OF BALLOON ANGIO-
PLASTY. In-hospital outcomes. Angiographic success rates of
balloon PTCA in diabetics (85%–96%) are usually similar to
those observed in nondiabetics (9,13). The composite end
point of mortality, nonfatal MI and urgent revascularization
was respectively 11.0% in diabetics versus 6.7% in nondia-
betics in the National Heart, Lung, and Blood Institute
Registry (p , 0.01), with higher mortality rates in diabetics
(3.2% vs. 0.5%) (13). However, lower mortality rates
(,0.5%), comparable with those of nondiabetics, were
reported by other groups (9,11,15). There were also evident
trends toward higher rates of urgent revascularization (9–
11,13) and acute coronary occlusion in diabetics (13).
SHORT- AND LONG-TERM FOLLOW-UP. It is well recognized
that restenosis rates may be very high (up to 63% in some
series) after PTCA in diabetics (14,116). Late clinical
outcome after PTCA in these patients is also often unfa-
vorable. Stein et al. (9) reported that five-year MI-free
survival was lower and that additional revascularization was
more frequently needed in 1,133 diabetics versus 9,300
nondiabetics undergoing PTCA. Similarly, Kip et al. (13)
found that nine-year mortality was twice as high in diabetic
patients treated by PTCA (35.9% vs. 17.9% in nondiabet-
ics), with significantly higher incidences of MI and repeat
revascularization. In the Bypass Angioplasty Revasculariza-
tion Investigation (BARI), post-PTCA five-year survival
was 73.3% in diabetics versus 91.3% in nondiabetics (p ,
0.0001). The benefit of CABG was most evident in IRDM
patients (10,11,16). Similar results were observed in the
Coronary Angioplasty versus Bypass Revascularization In-
vestigation (CABRI) (12), and a trend toward superiority of
CABG was observed in the BARI registry, even though
CAD was less extensive in PTCA than in surgical patients
(16,17). On the other hand, better CABG results were not
observed in the small subgroups of diabetics enrolled in the
first Randomized Intervention Treatment of Angina One
(RITA-1) study (23) and in the Emory Angioplasty versus
Surgery Trial (EAST) (24). Five-and 10-year survival rates
were similar in diabetic patients undergoing PTCA versus
CABG in the large nonrandomized series (n 5 2,639)
reported by Weintraub (15), and comparable six-year results
were also reported by Gum et al. in 525 diabetics (117).
Inability to fully revascularize all ischemic territories, high
restenosis rates and progression of atherosclerosis leading to
repeat revascularization procedures are the most frequently
suggested reasons for the long-term unfavorable results
(9,13–15,17,117,118).
In summary, in the majority of published series, PTCA in
diabetic patients is feasible with high angiographic success
rate. However, DM appears to be predictive of higher risk
of in-hospital complications, substantially increased reste-
nosis rates and relatively poor long-term outcome.
ROLE OF CORONARY STENTING. Most studies evaluating
stenting in diabetics are retrospective, and except for the
series of Elezi et al. (n 5 715 diabetics) (28), have enrolled
relatively small numbers of patients (116–121).
IN-HOSPITAL OUTCOMES. Angiographic success rates of
stenting in diabetics (92%–100%) are often similar to those
observed in nondiabetic patients (119–122). The composite
end point of mortality, nonfatal MI and urgent CABG,
ranging from 0.7% to 6.75%, is similar in diabetic versus
nondiabetic patients in most series (28,119). These in-
hospital complications after stent implantation compare
favorably to the 3% to 11% rates reported after balloon
PTCA in diabetics (9,13,15). However, Elezi et al. (28)
have found a clear trend toward higher rates of subacute
stent thrombosis in diabetics (3.2% vs. 2.0% in nondiabetics,
p 5 0.06). A similar trend was reported by Abizaid et al.
(119) in the IRDM patients.
SHORT- AND LONG-TERM FOLLOW-UP. Ranging from 24%
to 40%, angiographic restenosis rates after stenting in
diabetics were higher than the 20% to 27% rates observed in
nondiabetic patients (28,120). However, some reports have
found more favorable results in diabetics (116,122). In the
series reported by Van Belle et al. (116), restenosis rates
were similar (25% vs. 27%) after stenting, but different (63%
vs. 32%) after PTCA in diabetic versus nondiabetic patients.
In addition, major cardiac event-free survival is often
lower in diabetics (28,29,119,120); Elezi et al. (28) reported
a one-year event-free survival in diabetics of 73.1% versus
78.8% for nondiabetics (p , 0.001). However, long-term
outcome after stenting is not influenced by diabetic status,
according to other groups (116,122). Additional revascular-
ization was increased in target or new lesions in stented
diabetics (28,121), especially in the IRDM patients (119).
On the other hand, although some reports suggest that
multivessel coronary stenting is feasible in carefully selected
patients (with or without DM) with a high success rate, low
in-hospital major complications and favorable long-term
results (123,124), data concerning the role of this therapeu-
tic strategy in a specific diabetic population are not available.
In summary, stenting is feasible in diabetics with favorable
procedural and in-hospital success rates. However, angio-
graphic restenosis rates and long-term outcome after stent-
ing may be worse in this population, particularly in IRDM
patients.
MECHANISMS OF RESTENOSIS AND ROLE OF INSULIN. The
basic mechanisms responsible for restenosis after PTCA or
stenting in diabetics are unclear. The metabolic, hemato-
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logic and biological abnormalities observed in these patients
all participate in the complex restenotic reaction following
vessel injury (32). These patients’ coronary lesions are more
often associated with thrombus formation at angioscopy
(47), a predictor of late coronary occlusion after PTCA
(125). A recent study has shown that vessel occlusion is a
frequent mode of restenosis in diabetics undergoing con-
ventional balloon angioplasty (126). Moreover, intravascular
ultrasound data suggest that intimal hyperplasia is the main
reason for increased restenosis in both stented and non-
stented lesions in diabetics (127), and several studies have
found angiographic or ultrasound evidence consistent with
this mechanism (28,119,121). However, the results of some
groups reporting favorable restenosis rates after stenting in
diabetics do not appear to support the excessive intimal
hyperplasia hypothesis (116,122,126).
On the other hand, the multiple effects of insulin can
contribute to the pathogenesis of restenosis by inducing
smooth muscle cell migration and proliferation and extra-
cellular matrix production (32,44). Hyperinsulinemia can
lead to coronary vasospasm (128,129) and to thrombus
formation through stimulation of plasminogen-activator
inhibitor-1 and attenuation of fibrinolytic activity (45,46).
The poor short- and long-term results of coronary revascu-
larization in some IRDM patients also emphasize the major
role of this hormone (9,11,15,16,119). In addition, hyper-
insulinemia in patients with impaired glucose tolerance and
mild DM induces greater intimal hyperplasia after stent
implantation (130), and treatment by triglitazone, an insulin
sensitizer, reduces this intimal proliferation (131).
In summary, intimal hyperplasia and late vessel occlusion
are two potential mechanisms implicated in the complex
phenomenon of restenosis following angioplasty in diabet-
ics. However, further investigations should determine the
mechanisms of this reaction and evaluate the pejorative role
of insulin in restenosis.
ROLE OF GLYCOPROTEIN IIB/IIIA PLATELET RECEPTOR AN-
TAGONISTS. Data related to the usefulness of glycoprotein
IIb/IIIa receptor antagonists in diabetic patients are limited
to subgroup analyses from recent prospective randomized
trials. At least six trials of the effects of glycoprotein IIb/IIIa
inhibitors in patients undergoing coronary interventions
have been reported, four with abciximab, one with eptifi-
batide and one with tirofiban (25–27, 132–134). In the
EPIC trial, abciximab therapy showed a 35% reduction in
the primary end point of death, MI and urgent revascular-
ization at one month, with a similar risk reduction in DM
and non-DM patients (25). At three years, however, the
clinical benefits were sustained in the total population (135),
whereas diabetics experienced a progressive deterioration
with more clinical events than nondiabetics (136). In the
EPILOG trial, abciximab therapy in diabetic patients un-
dergoing elective PTCA led to a significant reduction of
death and MI at 30 days and at six months (26). However,
target vessel revascularization (TVR) at six months was
reduced only in the nondiabetic subgroup, and diabetics
treated with abciximab and standard-dose heparin had a
marginally greater benefit than those assigned to abciximab
and low-dose heparin. Pooled data from the EPIC,
EPILOG and EPISTENT trials showed that abciximab
decreases the one-year mortality of diabetic patients to that
of placebo-treated nondiabetic patients (137). In the
IMPACT-II trial, treatment with eptifibatide during coro-
nary intervention reduced rates of early abrupt closure and
ischemic events at 30 days; the benefit of therapy was similar
in patients with and without DM (133). In the RESTORE
trial, tirofiban reduced early cardiac events in patients
undergoing PTCA for acute coronary syndromes, but this
effect was no longer statistically significant at 30 days (134).
Twenty percent of all patients in this trial were diabetics;
however, no subgroup analysis was reported.
The EPISTENT trial was the largest study evaluating the
benefit of abciximab therapy in patients undergoing coro-
nary stenting (27,138). It demonstrated a significant reduc-
tion of major cardiac events at 30 days and at six months in
the abciximab groups compared with the stent-plus-placebo
group. In addition, the combination of stenting and abcix-
imab therapy among diabetic patients resulted in a signifi-
cant reduction in six-month rates of death, MI and TVR
compared with stent plus placebo or balloon angioplasty
plus abciximab therapy (138). The substantial TVR reduc-
tion associated with a significant increase in angiographic
net gain and a trend toward a decrease in late loss index in
stented diabetics treated by abciximab versus those treated
with placebo suggests for the first time a potential additional
benefit of abciximab in reducing restenosis in stented
diabetics (138, 139). In this context, the ERASER trial has
provided intravascular ultrasound data suggesting that,
compared with placebo, abciximab decreases neointimal
proliferation in stented diabetics but not in the overall study
population (140).
In summary, the EPISTENT trial demonstrates a signif-
icant reduction of major ischemic cardiac events and TVR
in stented diabetic patients and confirms the net benefit of
glycoprotein IIb/IIIa antagonists in this population. How-
ever, further investigations are needed to explain the inter-
action of abciximab with DM status and whether a similar
reduction in coronary restenosis will be observed with other
glycoprotein IIb/IIIa antagonists.
CABG in patients with symptomatic CAD and DM. Diabe-
tes mellitus is a recognized risk factor for poor early and late
outcome after CABG (18–22), and is also identified as an
important predictor of progression and occlusion of by-
passed and nonbypassed coronary segments (20,24).
As discussed above, the BARI randomized trial (10,11),
and to a lesser extent the BARI registry (16), have shown
that patients with DM and multivessel disease assigned to
an initial strategy of CABG have a striking reduction in
cardiac mortality compared with PTCA. Post-hoc analyses
were also performed in subsets of diabetic patients in three
smaller randomized trials comparing PTCA and CABG.
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Results similar to those of BARI were obtained in one trial
(12), but CABG outcome was not superior to that of PTCA
in the two other trials (23,24). Large retrospective databases
of diabetic patients who have undergone coronary interven-
tion procedures may not be suitable to compare CABG and
percutaneous intervention because patients in the two treat-
ment groups are almost certainly not comparable in terms of
prognosis. Be that as it may, two large databases of patients
with multivessel CAD from Emory (15) and Duke (22)
university studies assessing the results of revascularization
procedures in diabetic patients have been reported. In the
Emory study, only the IRDM subgroup treated by PTCA
had lower five- and 10-year survival rates than the CABG
group (15). In the Duke study, DM was associated with
worse five-year survival, but the effect of DM on prognosis
was similar in both treatment strategies (22).
In patients undergoing CABG, the superiority in terms
of long-term survival of internal mammary artery (IMA)
conduits to the left anterior descending coronary artery over
autologous saphenous vein grafts is well established (141).
Therefore, it is not surprising that the benefit of CABG in
the diabetic subgroup in BARI was confined to those
receiving at least one IMA graft (10,11). Whether bilateral
IMA grafting confers yet an additional benefit in these
patients is not known, particularly because this technique
carries a greater risk of sternal wound complications in
diabetics than in nondiabetics (142–144). However, DM
should not be an absolute contraindication to bilateral IMA
use, which should be adjusted to the coronary bed needing
revascularization and to the patient’s age (144).
In summary, the superiority of CABG over PTCA in
diabetics is not well established. Conclusions drawn from
the diabetic subgroup of the BARI trial must be confirmed
in larger randomized trials.
Summary and future directions. The optimal strategy of
coronary revascularization in diabetics remains to be deter-
mined. Many biological, hematological and metabolic ab-
normalities predispose diabetic patients undergoing percu-
taneous revascularization to a high incidence of in-hospital
and long-term cardiovascular events, presumably because of
incomplete revascularization, high restenosis rates and
CAD progression. Whether stents will improve outcome in
this population is still controversial, and prospective inves-
tigation of this issue is required. Moreover, the superiority
of a surgical strategy over percutaneous revascularization in
this population remains unproven. These conclusions were
drawn from trials done at the end of the 1980s and
beginning of the 1990s, when stents were emerging and the
important class of GP IIb/IIIa inhibitors had not yet been
developed. These two important catheter-based advances
should have a positive influence on clinical outcome in
future investigations, as suggested by the results of the
diabetic subgroup in the EPISTENT study. Locally deliv-
ered ionizing radiation and gene therapy may also have a
potential role in this high-risk population. Furthermore,
treatment advances are not confined to interventional car-
diology, as less invasive surgical techniques may offer ad-
vantages over conventional CABG. Final results from the
two European randomized trials of stenting versus CABG
(Arterial Revascularization Therapy Study [ARTS] and
Stent or Surgery [SOS]) will probably shed some new light
on coronary revascularization in diabetic patients. More-
over, the demonstrated benefit of strict glycemic, lipid and
blood pressure control indicate that this management strat-
egy should be routinely enforced in these patients and that
their effect after coronary revascularization should be pro-
spectively evaluated. Data from the planned BARI-II trial,
which will randomize diabetic patients and will include
coronary stenting as well as intensive glycemic and lipid
control, should answer the major questions concerning
therapeutic strategies in this population.
In conclusion, many aspects related to coronary revascu-
larization in diabetics remain unclear, and further random-
ized investigations evaluating the latest new progress in
percutaneous as well as surgical revascularization will help
physicians make better therapeutic decisions. Until the
results of ongoing and future trials are available, manage-
ment of CAD in patients with DM will continue to pose a
challenge to the medical profession.
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